English

Nomination committee appointed in IRLAB

Report this content

In preparation for the annual general meeting 2019, the company’s three largest shareholders, or groups of shareholders, have appointed members of the nomination committee. The nomination committee consists of Bo Rydlinger, Daniel Johnsson and Olle Stenberg beside Anders Vedin, the chairman of the board. The nomination committee represents almost 58 per cent of shares and votes in the company.

According to the instruction for appointment of the nomination committee in IRLAB Therapeutics AB that was resolved at the annual general meeting on May 16, 2018, the nomination committee shall, besides the chairman of the board, consist of representatives of the three largest shareholders, or groups of shareholders, as per August 31.

As the three largest shareholders or groups of shareholders now have appointed their representatives, the nomination committee consists of the following members:

  • Bo Rydlinger, background from banking and investments, appointed by a group of shareholders representing almost 24 per cent of shares and votes;
  • Daniel Johnsson, entrepreneur, business developer and investor, appointed by a group of shareholders representing more than 21 per cent of shares and votes;
  • Olle Stenberg, experience from business development and management, appointed by a group of shareholders that consists of the company’s founders representing more than 13 percent of shares and votes; and
  • Anders Vedin, chairman of the board of IRLAB Therapeutics AB.

Information about the nomination committee’s work and the instruction to the nomination committee can be found on the company webside www.irlab.se/corporate-governance/nomination-committee/. The nomination committee’s proposal will be presented in the notice to the annual general meeting 2019 and on the company’s web page, www.irlab.se.

Shareholders who wish to submit proposals to the nomination committee may contact the nomination committee at the company’s address or e-mail - info@irlab.se. In order to enable the nomination committee to take proposals into consideration they must be submitted in good time prior to the annual general meeting and no later than January 31, 2019.

For more information

Anders Vedin, chairman of the board
Phone: +46 70 876 15 70
E-mail: anders.vedin@irlab.se

About IRLAB

IRLAB is a research and development company, listed on Nasdaq First North Premier, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease.

IRLAB has two clinical candidate drugs, IRL752 and IRL790, focused on medical needs in Parkinson’s disease. IRLAB also has additional programs in pre-clinical stages.

IRLAB’s research is aimed at discovery and development of new candidate drugs addressing unmet medical need in diseases of the central nervous system, using the unique and proprietary integrative screening process, ISP.

IRLAB is based in Gothenburg, Sweden. The operations are mainly carried out through the subsidiary Integrative Research Laboratories Sweden AB.

For more information, please visit www.irlab.se.

Documents & Links